Find molecules with rising US import demand and no active US FDA DMF. The domestic-sourcing candidate list, sized from real trade flows.
Lenalidomide carries 117 active US ANDAs but zero US-based active FDA Type II DMFs. Mesalamine has 1 US DMF against $126M of US imports growing 120% in two years. Gabapentin: 0 US DMFs against $100M of US imports. Each pattern is the same: a blockbuster molecule with rising US demand, no domestic API capacity, and a structural import dependency. The reshoring opportunity is the gap between the import value and the (often zero) domestic supply path.
| # | Molecule | 2024 US imports | 2-year growth | Active US DMFs | Posture |
|---|---|---|---|---|---|
| 1 | Mesalamine | Gastro · oncology adjacent | 1 active US DMFs | $126M · +121% | NAI |
| 2 | Gabapentin | Neurology | 0 active US DMFs | $99.7M · +37% | NAI |
| 3 | Metoprolol | Cardiovascular | 2 active US DMFs | $62.2M · +118% | NAI |
| 4 | Amoxicillin | Antibiotic | 0 active US DMFs | $40.5M · +60% | VAI |
| 5 | Lenalidomide | Oncology · blockbuster | 0 active US DMFs | $3M growing | NAI |
A single molecule or the basket. Default scope is the US destination market; the same logic applies to EU reshoring under EMA criteria.
US import value (two-year growth), active US-based FDA DMF count, and the implied domestic-supply gap. Computed against the api_docs and plants catalog.
Citation-anchored brief ranked by import growth and DMF gap. Handoff to CMO scouting or domestic-supplier qualification.
Reshoring candidates rank by US import growth, not just absolute import value. A 120% growth on $126M is a different opportunity than a flat $200M lane.
Zero or one active US-based FDA DMF on a growing-imports molecule is the textbook reshoring case. The gap is the size of the qualification investment needed.
DMFs are attributed to specific plants via v_api_doc_plants. A US-state-level view of where capacity exists today (and where it doesn't) feeds the CMO scouting workflow.
Drug supply chain security policies in the US prioritise domestic API capacity. The radar surfaces the prioritised molecules ranked by both demand and policy weight.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Twelve molecules with US import demand and varying US-based DMF coverage · count is active US-based FDA Type II DMFs · the gap signal.
The reshoring radar is the domestic-sourcing prioritisation list. PharmaDB joins US import flows to the FDA DMF register, attributes DMFs to US-based plants, and surfaces molecules where demand exceeds domestic supply. The view is molecule_country_flow (US destination) joined to api_docs and v_api_doc_plants.
A molecule with US import value above $5M, two-year growth above 30%, and fewer than 2 active US-based FDA Type II DMFs. All three thresholds are tunable. The defaults surface the structural domestic-supply gaps.
The FDA Type II DMF register joined to v_api_doc_plants to attribute each DMF to its manufacturing plant, filtered to plants located in the United States. Active status only.
Lenalidomide is positioned as a next-tier candidate because the US generic filing density (117 ANDAs) implies imminent post-LOE demand, even though the API import trade has not yet built. The radar surfaces both observed-demand and pipeline-demand candidates.
Yes. Swap the destination filter to EU member states and the DMF gate to EDQM CEP holders. Same methodology, same shape of output. The EU version typically returns a thinner list because the EU API base is structurally larger.
Dual-source finds a second exporter on the same lane. Reshoring finds a domestic origin where none exists today. They run in parallel: dual-source handles the operational risk, reshoring handles the strategic supply chain security goal.
Trade aggregates refresh weekly. DMF and plant attribution refresh weekly. The radar recomputes on every refresh. The catalog row carries the last-computed timestamp surfaced on every result page.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.